MARKET

ENGN

ENGN

enGene Holdings Inc.
NASDAQ
8.30
-0.43
-4.93%
Opening 14:23 01/06 EST
OPEN
8.67
PREV CLOSE
8.73
HIGH
8.87
LOW
8.22
VOLUME
91.88K
TURNOVER
--
52 WEEK HIGH
11.14
52 WEEK LOW
2.650
MARKET CAP
555.97M
P/E (TTM)
-3.6170
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ENGN last week (1229-0102)?
Weekly Report · 1d ago
Weekly Report: what happened at ENGN last week (1222-1226)?
Weekly Report · 12/29/2025 09:10
enGene Holdings: A Potential Oncology Entrant
Seeking Alpha · 12/26/2025 21:00
3 ‘Strong Buy’ Stocks to Buy Today,12/26/2025, According to Top Analysts
TipRanks · 12/26/2025 14:25
Oppenheimer Remains a Buy on enGene Holdings (ENGN)
TipRanks · 12/24/2025 14:15
3 ‘Strong Buy’ Stocks to Buy Today,12/24/2025, According to Top Analysts
TipRanks · 12/24/2025 13:19
Reaffirming Buy on enGene: Strengthened LEGEND Phase 2 Data, Robust Cash Runway to 2028, and Path to 2026 BLA for Detalimogene
TipRanks · 12/24/2025 12:35
Analysts Offer Insights on Healthcare Companies: enGene Holdings (ENGN) and Agios Pharma (AGIO)
TipRanks · 12/24/2025 12:30
More
About ENGN
enGene Holdings Inc. is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. The Company’s lead program is detalimogene voraplasmid, (detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase II study, which includes a cohort studying detalimogene in Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (Cis). Detalimogene is being developed through its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA. The Company is developing non-viral genetic medicines based on its DDX gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.

Webull offers enGene Holdings Inc stock information, including NASDAQ: ENGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ENGN stock methods without spending real money on the virtual paper trading platform.